IonGate Biosciences Closes Second Round of Financing with Heidelberg Innovation

Lars-Eric Utterman joins Supervisory Board

08-Nov-2004

The Frankfurt-based biotech company IonGate Biosciences has closed a second round of financing with its previous investor, Heidelberg Innovation. IonGate has developed a biosensor system for preclinical drug research with transporter proteins. These proteins play an important role in various indication areas such as heart and circulation diseases as well as CNS- and metabolism-related disorders. The acquired capital will be used to continue the development and subsequent marketing of IonGate's pathbreaking platform technology. As part of the renewed investment, Lars-Eric Uttermann, Vice President Commercial Initiatives of Amersham Biosciences, will join IonGate's supervisory board.

"IonGate's technology, which is equally robust and sensitive, allows the intense investigation of electrogenic transporters for the first time, thus opening new perspectives for drug research in important indication areas," explains Christoph Kronabel, Managing Partner of Heidelberg Innovation. He is convinced of the marketability of the Frankfurt biotech company, with strong evidence being the impressive list of customers as well as the already achieved turnover. "Furthermore, we have been able to gain a highly professional member of the supervisory board: Owing to his experience, Lars-Eric Utterman of Amersham Biosciences will significantly contribute towards the establishment of IonGate's technology as the gold standard within the transporter market," says Krona-bel.

Thiemo Gropp, managing director of IonGate, also sees Lars Utter-man's commitment as confirmation of the market potential of his com-pany. "Mr. Utterman's decision for IonGate is just like a very positive external validation of the company, a fact which I am very pleased about. His decision demonstrates the confidence in our technology and in the future success of our company, just like the further commitment from Heidelberg Innovation does."

https://www.bionity.com/en/news/40691/iongate-biosciences-closes-second-round-of-financing-with-heidelberg-innovation.html